| Title |
The GH1/IGF-1 axis polymorphisms and their impact on breast cancer development
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, November 2006
|
| DOI | 10.1007/s10549-006-9411-9 |
| Pubmed ID | |
| Authors |
Kerstin Wagner, Kari Hemminki, Asta Försti |
| Abstract |
The growth hormone 1/insulin-like growth factor-1 (GH1/IGF-1) axis plays an essential role in the development of the breast by regulating cell proliferation, differentiation and apoptosis. Imbalances within this axis lead to an aberrant signalling and recent research has focussed on the overexpression of these growth factors and their involvement in breast cancer development. The increased understanding of the molecular mechanisms and signalling pathways connected to the GH1/IGF-1 axis has provided important insights into aetiology, prevention and therapy for breast cancer. However, to identify the contribution of the GH1/IGF-1 signalling pathway to cancer risk still remains a challenge since the results of various studies are controversial. Here, we discuss the influence of low-penetrance polymorphisms in the genes along the GH1/IGF-1 axis and their impact on hormone levels and cancer risk, especially breast cancer. We point out what is known about the effects of the variants and show how the interaction of genetic variants affects breast cancer risk. |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 4% |
| Unknown | 22 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 17% |
| Professor > Associate Professor | 3 | 13% |
| Student > Postgraduate | 2 | 9% |
| Student > Ph. D. Student | 2 | 9% |
| Student > Bachelor | 1 | 4% |
| Other | 4 | 17% |
| Unknown | 7 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 5 | 22% |
| Medicine and Dentistry | 5 | 22% |
| Agricultural and Biological Sciences | 5 | 22% |
| Chemical Engineering | 1 | 4% |
| Unknown | 7 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 November 2007.
All research outputs
#7,453,827
of 22,787,797 outputs
Outputs from Breast Cancer Research and Treatment
#1,658
of 4,655 outputs
Outputs of similar age
#24,213
of 69,646 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#17
of 33 outputs
Altmetric has tracked 22,787,797 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,655 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 69,646 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one is in the 6th percentile – i.e., 6% of its contemporaries scored the same or lower than it.